Source:http://linkedlifedata.com/resource/pubmed/id/10875273
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
2000-7-20
|
pubmed:abstractText |
Insulin-like growth factor I (IGF-I) is an important growth factor for bone, yet the mechanisms that mediate its anabolic activity in the skeleton are poorly understood. To examine the effects of locally produced IGF-I in bone in vivo, we targeted expression IGF-I to osteoblasts of transgenic mice using a human osteocalcin promoter. The IGF-I transgene was expressed in bone osteoblasts in OC-IGF-I transgenic mice at high levels in the absence of any change in serum IGF-I levels, or of total body growth. Bone formation rate at the distal femur in 3-week-old OC-IGF-I transgenic mice was approximately twice that of controls. By 6 weeks, bone mineral density as measured by dual energy x-ray, and quantitative computed tomography was significantly greater in OC-IGF-I transgenic mice compared with controls. Histomorphometric measurements revealed a marked (30%) increase femoral cancellous bone volume in the OC-IGF-I transgenic mice, but no change in the total number of osteoblasts or osteoclasts. Transgenic mice also demonstrated an increase in the osteocyte lacunea occupancy, suggesting that IGF-I may extend the osteocyte life span. We conclude that IGF-I produced locally in bone osteoblasts exerts its anabolic effect primarily by increasing the activity of resident osteoblasts.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0013-7227
|
pubmed:author |
pubmed-author:ChernausekS DSD,
pubmed-author:ClemensT LTL,
pubmed-author:DonahueL RLR,
pubmed-author:FabioG PGP,
pubmed-author:GengZZ,
pubmed-author:LangubM CMC,
pubmed-author:MallucheH HHH,
pubmed-author:Monier-FaugereM CMC,
pubmed-author:NakayamaTT,
pubmed-author:PikeJ WJW,
pubmed-author:RosenC JCJ,
pubmed-author:ZhaiMM
|
pubmed:issnType |
Print
|
pubmed:volume |
141
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2674-82
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:10875273-Animals,
pubmed-meshheading:10875273-Body Weight,
pubmed-meshheading:10875273-Bone Development,
pubmed-meshheading:10875273-Cell Division,
pubmed-meshheading:10875273-Femur,
pubmed-meshheading:10875273-Gene Expression,
pubmed-meshheading:10875273-Humans,
pubmed-meshheading:10875273-Insulin-Like Growth Factor I,
pubmed-meshheading:10875273-Mice,
pubmed-meshheading:10875273-Mice, Transgenic,
pubmed-meshheading:10875273-Osteoblasts,
pubmed-meshheading:10875273-Osteocalcin,
pubmed-meshheading:10875273-Osteocytes,
pubmed-meshheading:10875273-Transgenes
|
pubmed:year |
2000
|
pubmed:articleTitle |
Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation.
|
pubmed:affiliation |
Department of Medicine, University of Cincinnati College of Medicine, Ohio 45267, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.
|